SCLEROLYM Trial
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Cytolytic CD4+ T cells
What it measured
Main measures
Primary endpoint is safety. Safety will be evaluated with the help of the following parameters:
Safety
Other measures (1)
Efficacy parameters are secondary endpoints and include:
Who could take part
Relapsing MS
Inclusion: • Males and females 18 to 60 years of age Exclusion: • Positive only for the HLA DRB1*0101, DRB1*0102, DRB1*0401, DRB1*0426 alleles or for the combination of the previous alleles.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective is to evaluate the safety of a treatment with autologous CD4+ cells, stimulated and expanded ex vivo by a myelin oligodendrocyte glycoprotein peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope by means of AE reports, vital signs, physical examination, and laboratory evaluation
Loading reviews and guidelines…
History
Started
Dec 2014
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error